Prostate Health Index (phi) is now available.

Discover how phi can guide better prostate cancer detection and management.

Featured urology tests

Prostate Health Index (phi)

Prostate Health Index (phi)

phi is designed to aid in distinguishing prostate cancer from benign prostatic conditions in patients aged 50 years and older with total PSA ≥4.0 to ≤10.0 ng/mL with digital rectal examination findings that are not suspicious for cancer
 

VistaSeq®

VistaSeq®

VistaSeq® Prostate Panel assay is intended for patients with a personal history of prostate cancer or a family history consistent with an inherited cancer syndrome. In addition, the National Comprehensive Cancer Network (NCCN) Guidelines recommend that patients diagnosed with Grade Group (GG) 1-3 prostate cancers and a suspicious family history should undergo germline testing, and those with GG4 and 5 prostate cancers should be tested as well (source Prostate Cancer. NCCN Guidelines for Patients®, Version 2.2021)

OmniSeq® INSIGHT

OmniSeq® INSIGHT

NGS-based genomic and immune profiling assay including RNA-seq, TMB, MSI, and PD-L1 IHC. Comprehensive genomic and immune profiling gives a complete picture of a patient's tumor and details specific treatment options in one easy to-interpret report